Skip to main content
SpringerLink
Log in

Kosten in der Früh- und Spätphase des Diabetes mellitus

Costs involved in the early and late phases of diabetes mellitus

  • Schwerpunkt: Diabetes mellitus
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Die Kosten des Diabetes mellitus Typ 2 in Deutschland werden aufgrund lückenhafter Erhebung unterschätzt. Gerade in den ersten Erkrankungsjahren sind die Kosten signifikant höher als bei durchschnittlichen Versicherten und den übrigen Patienten mit Diabetes. Kostentreiber sind schon hier stationäre Behandlungen von Diabeteskomplikationen. Blutzuckersenkende Medikamente allein spielen eine untergeordnete Rolle. Diese Kostenstruktur bleibt auch in den späteren Diabetesstadien nach neueren Erhebungen (CODE-2, CoDiM) gleich. Patienten mit komplexen Folgeerkrankungen verursachen durchschnittlich mehr als das 4-Fache an Kosten als andere Versicherte. Die enormen direkten Kosten des Diabetes machen 14,2% der gesamten Gesundheitsausgaben Deutschlands aus. Blutdruck- und Blutzuckereinstellung scheinen kosteneffektiv zu sein, während die Datenlage zur Blutfettsenkung mit modernen Therapien noch unklar ist. Daher ist ein Vorgehen nach den aktuellen Leitlinien und der ärztlichen Ethik anzuraten.

Abstract

The costs of diabetes mellitus type 2 in Germany are underestimated due to incomplete data. Especially in the first few years of the disease, the costs are significantly higher in diabetics than in persons without diabetes or other diabetes patients. The cost driver is inpatient treatment of diabetes complications. Glucose-lowering medications play a minor role. According to recent studies (CODE-2, CoDiM), the basic cost structure remains similar in later diabetes stages. For patients with complex complications, the costs are more than four times higher than in persons without diabetes. The enormous direct costs of diabetes account for 14.2% of total health care costs in Germany. Therapy for high blood pressure and blood glucose seem to be cost effective; data for modern lipid-lowering therapies are unclear. Thus, it is advisable to treat patients according to current guidelines and ethical considerations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Brown JB, Nichols GA, Glauber HS et al. (1999) Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care 22: 1116–1124

    Article  PubMed  CAS  Google Scholar 

  2. CDC Diabetes Cost-effectiveness Group (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287: 2542–2551

    Article  Google Scholar 

  3. Clarke PM, Gray AM, Briggs A et al. (2005) Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 48: 868–877

    Article  PubMed  CAS  Google Scholar 

  4. Diabetes-Union D (Hrsg) (2006) Deutscher Gesundheitsbericht Diabetes 2007. Kirchheim, Mainz

  5. Greiner W, Krummaker S, Graf von der Schulenburg JM et al. (2006) Krankheitskostenanalyse eines neu aufgetretenen Diabetes mellitus Typ 2. Diabetologie 1: 237–244

    Article  Google Scholar 

  6. Hauner H (2006) [The costs of diabetes mellitus and its complications in Germany.]. Dtsch Med Wochenschr 131 (Suppl 8): S240–S242

    Article  PubMed  Google Scholar 

  7. Hauner H, Koster I, Ferber L von (2003) [Prevalence of diabetes mellitus in Germany 1998–2001. Secondary data analysis of a health insurance sample of the AOK in Hesse/KV in Hesse]. Dtsch Med Wochenschr 128: 2632–2637

    Article  PubMed  CAS  Google Scholar 

  8. Koster I, Hauner H, Ferber L von (2006) [Heterogeneity of costs of diabetic patients: the cost of diabetes mellitus study]. Dtsch Med Wochenschr 131: 804–810

    Article  PubMed  CAS  Google Scholar 

  9. Koster I, Ferber L von, Ihle P et al. (2006) The cost burden of diabetes mellitus: the evidence from Germany – the CoDiM study. Diabetologia 49: 1498–1504

    Article  PubMed  CAS  Google Scholar 

  10. Liebl A, Neiss A, Spannheimer A et al. (2001) [Costs of type 2 diabetes in Germany. Results of the CODE-2 study]. Dtsch Med Wochenschr (1946) 126: 585–589

    Article  Google Scholar 

  11. Liebl A, Neiss A, Spannheimer A et al. (2002) Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany – results from the CODE-2 study. Exp Clin Endocrinol Diabetes 110: 10–16

    Article  PubMed  CAS  Google Scholar 

  12. Liebl A, Spannheimer A, Reitberger U et al. (2003) Arzneimitteltherapie und Medikationskosten von Patienten mit Diabetes Typ 2 in Deutschland. Diabetes und Stoffwechsel 12: 145–151

    Google Scholar 

  13. Liebl A, Spannheimer A, Reitberger U et al. (2002) [Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study]. Med Klin 97: 713–719

    Article  Google Scholar 

  14. Mihaylova B, Briggs A, Armitage J et al. (2005) Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet 365: 1779–1785

    Article  PubMed  Google Scholar 

  15. Nichols GA, Brown JB (2002) The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care 25: 482–486

    Article  PubMed  Google Scholar 

  16. Rathmann W, Haastert B, Icks A et al. (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46: 182–189

    PubMed  CAS  Google Scholar 

  17. Schiel R, Muller UA, Stein G (2005) [Costs of therapy of insulin-treated patients with diabetes mellitus in Germany. Results of the JEVIN trial]. Med Klin 100: 453–461

    Article  Google Scholar 

  18. Schramm W, Schoffski O, Gortz A et al. (2004) [Disease modelling in diabetes mellitus]. Dtsch Med Wochenschr 129: 2305–2310

    Article  PubMed  CAS  Google Scholar 

  19. Ferber L von, Koster I, Hauner H (2006) [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study]. Med Klin 101: 384–393

    Article  Google Scholar 

  20. Ferber L von, Koster I, Hauner H (2007) Medical costs of diabetic complications total costs and excess costs by age and type of treatment results of the German CoDiM Study. Exp Clin Endocrinol Diabetes 115: 97–104

    Article  Google Scholar 

  21. Wabitsch M, Hauner H, Hertrampf M et al. (2004) Type II diabetes mellitus and impaired glucose regulation in Caucasian children and adolescents with obesity living in Germany. Int J Obes Relat Metab Disord 28: 307–313

    PubMed  CAS  Google Scholar 

  22. WHO (2004) Diabetes action now – An initiative of the World Health Organization and the International Diabetes Federation. Geneva

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Diabetes- und Stoffwechselzentrum, Fachklinik Bad Heilbrunn, Wörnerweg 30, 83670, Bad Heilbrunn, Deutschland

    A. Liebl

Authors
  1. A. Liebl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Liebl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liebl, A. Kosten in der Früh- und Spätphase des Diabetes mellitus. Internist 48, 708–714 (2007). https://doi.org/10.1007/s00108-007-1875-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-007-1875-0

Schlüsselwörter

Keywords

Search

Navigation